Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. ...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
28 September 2022
|
| In: |
Blood cancer journal
Year: 2022, Volume: 12, Issue: 9, Pages: 1-10 |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/s41408-022-00729-y |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41408-022-00729-y Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41408-022-00729-y |
| Author Notes: | Kavita Raj, Dirk-Jan Eikema, Vipul Sheth, Linda Koster, Liesbeth C. de Wreede, Didier Blaise, Carmela Di Grazia, Yener Koc, Victoria Potter, Patrice Chevallier, Lucia Lopez- Corral, Depei Wu, Stephan Mielke, Johan Maertens, Ellen Meijer, Anne Huynh, Jakob Passweg, Thomas Luft, Jose Antonio Pérez-Simón, Fabio Ciceri, Agnieszka Piekarska, G. Hayri Ozsan, Nicolaus Kröger, Marie Robin and Ibrahim Yakoub-Agha |
| Summary: | Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. ... |
|---|---|
| Item Description: | Gesehen am 07.11.2023 |
| Physical Description: | Online Resource |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/s41408-022-00729-y |